September 29th 2012
Combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in patients with melanoma that had BRAF V600 mutations.
Gefitinib improved progression-free survival and some quality of life measures when used as second-line therapy for esophageal cancer.
September 20th 2012
Coverage from the 2012 European Society for Medical Oncology congress, held at the Austria Center Vienna from September 28 - October 2, in Vienna, Austria.